Therapeutic prospects of microRNAs in cancer treatment through nanotechnology

被引:39
作者
Awasthi, Rajendra [1 ]
Rathbone, Michael John [2 ,3 ]
Hansbro, Philip Michael [4 ]
Bebawy, Mary [3 ]
Dua, Kamal [3 ,4 ]
机构
[1] NKBR Coll Pharm & Res Ctr, Meerut 45206, Uttar Pradesh, India
[2] ULTI Pharmaceut, Hamilton 3204, New Zealand
[3] Univ Technol Sydney, Grad Sch Hlth, Discipline Pharm, Sydney, NSW, Australia
[4] Univ Newcastle, Hunter Med Res Inst, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia
关键词
Cancer; Extracellular vesicles; MicroRNA; Microparticles; Nanotechnology; Multidrug resistance; Metastasis; P-Glycoprotein; DRUG-DELIVERY; NONSMALL CELL; IN-VIVO; INTERCELLULAR TRANSFER; TUMOR-SUPPRESSOR; CURRENT PROGRESS; PHASE-II; NANOPARTICLE; FUTURE; MIRNA;
D O I
10.1007/s13346-017-0440-1
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
MicroRNAs (miRNAs) represent a new class of diagnostic and prognostic biomarker as well as new therapeutic targets in cancer therapy. miRNAs are gaining significant interest due to extensive advancements in knowledge since their discovery and, more recently, their translational application as therapeutic moieties and targets in the management of disease. miRNAs used in the treatment of cancer would position them as a new class of emerging therapeutic agents. Indeed, numerous candidate miRNAs have been identified as having therapeutic application in the treatment of cancer, but there is still much to learn about how to transform these into effective, patient-compliant, and targeted drug delivery systems. In this mini review, we discuss the utility and potential of nanotechnology in miRNA formulation and delivery with particular emphasis on cancer, including their role in conferring multidrug resistance and metastatic capacity. This review benefits both the formulation and biological scientists in understanding and exploring the new vistas of miRNA delivery using nanotechnology in the cancer clinically.
引用
收藏
页码:97 / 110
页数:14
相关论文
共 133 条
[1]   Nanomaterial standards for efficacy and toxicity assessment [J].
Adiseshaiah, Pavan P. ;
Hall, Jennifer B. ;
McNeil, Scott E. .
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2010, 2 (01) :99-112
[2]  
Alizadeh Shaban, 2016, Int J Hematol Oncol Stem Cell Res, V10, P172
[3]  
[Anonymous], 2016, J NANOMED NANOTECHNO, DOI DOI 10.1016/J.JCONREL.2014.09.001
[4]  
[Anonymous], 2014, MIRBASE SEQUENCE DAT
[5]  
[Anonymous], 2014, SAF STUD MBP 426 LIP
[6]   Nanotechnology in cancer therapy [J].
Aslan, Burcu ;
Ozpolat, Bulent ;
Sood, Anil K. ;
Lopez-Berestein, Gabriel .
JOURNAL OF DRUG TARGETING, 2013, 21 (10) :904-913
[7]  
Awasthi R., 2016, Current Nanomedicine (Formerly: Recent Patents on Nanomedicine), V6, P78, DOI 10.2174/2468187306666160808160330
[8]  
Azimzadeh Mostafa, 2017, Nanomedicine Research Journal, V2, P36, DOI 10.22034/nmrj.2017.23336
[9]   Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma [J].
Babar, Imran A. ;
Cheng, Christopher J. ;
Booth, Carmen J. ;
Liang, Xianping ;
Weidhaas, Joanne B. ;
Saltzman, W. Mark ;
Slack, Frank J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (26) :E1695-E1704
[10]   DIFFUSION OF UNIVALENT IONS ACROSS LAMELLAE OF SWOLLEN PHOSPHOLIPIDS [J].
BANGHAM, AD ;
STANDISH, MM ;
WATKINS, JC .
JOURNAL OF MOLECULAR BIOLOGY, 1965, 13 (01) :238-+